IMPROVED HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH OFATUMUMAB PLUS CHLORAMBUCIL OR CHLORAMBUCIL
Author(s)
Hillmen P1, Haiderali A2, Chang C3
1St. James University Hospital, Leeds, UK, 2GlaxoSmithKline, Collegeville, PA, USA, 3GlaxoSmithKline, Research Triangle Park, NC, USA
OBJECTIVES: The COMPLEMENT 1 trial demonstrated significantly better progression-free survival with ofatumumab combined with chlorambucil (O+CHL) [22.4 months] versus chlorambucil alone (CHL) [13.1 months] in patients with chronic lymphocytic leukemia . The impact on health-related quality of life (HRQoL) was also assessed. METHODS:
Conference/Value in Health Info
2014-05, ISPOR 2014, Palais des Congres de Montreal
Value in Health, Vol. 17, No. 3 (May 2014)
Code
PCN155
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
Oncology